PALB2 and neoplasm: A separate genomic analysis by Seeber et al. reported increased TMB and higher rates of dMMR in BRCA1-, BRCA2-, and PALB2-mutated PDAC; samples with the BRCA1 or BRCA2 pathogenic variants also expressed PDL1 (defined by ≥1% on tumor cells) more frequently [63].